COVID-Lung: The Battlefield

J Pediatr Intensive Care 2021; 10(01): 001-003
DOI: 10.1055/s-0040-1716907

Editorial

Benan Bayrakci

¹Division of Pediatrics, Department of Pediatric Intensive Care Medicine, ECMO Program, Hacettepe University Faculty of Medicine, Ankara, Turkey

References
1 Orso D, Federici N, Copetti R, Vetrugno L, Bove T. Infodemic and the spread of fake news in the COVID-19-era. Eur J Emerg Med 2020; 27 (05) 327-328
2 Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19?. JAMA Intern Med 2020; 180 (09) 1152-1154 . Doi:10.1001/jamainternmed.2020.3313
3 Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39 (05) 405-407
4 Kesici S, Yavuz S, Bayrakci B. Get rid of the bad first: therapeutic plasma exchange with convalescent plasma for severe COVID-19. Proc Natl Acad Sci U S A 2020; 117 (23) 12526-12527
5 Kesici S, Tanyıldız M, Yetimakman F, Bayrakci B. A novel treatment strategy for severe Guillain-Barré syndrome: zipper method. J Child Neurol 2019; 34 (05) 277-283
6 Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not?. Crit Care 2020; 24 (01) 154
7 Yao XH, Li TY, He ZC. , et al. Zhonghua Bing Li Xue Za Zhi A pathological report of three COVID-19 cases by minimally invasive autopsies. Chin J Pathol 2020; 49 (05) 411-417 . Doi:10.3760/cma.j.cn112151-20200312-00193
8 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280.e8
9 Yavuz S, Kesici S, Bayrakci B. Physiological advantages of children against COVID-19. Acta Paediatr 2020; 109 (08) 1691